Overview

A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety & tolerability of noscapine HCl in patients with advanced multiple myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Cougar Biotechnology, Inc.
Treatments:
Noscapine